Summary & Overview
CPT 78816: Whole Body PET/CT Imaging for Diagnostic Evaluation
CPT code 78816 is a critical billing code for whole body positron emission tomography (PET) scans with concurrently acquired computed tomography (CT), used for attenuation correction and anatomical localization. This advanced diagnostic imaging procedure is widely utilized in the evaluation and management of various conditions, particularly in oncology for cancer staging and follow-up. The code is recognized by major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, reflecting its broad clinical and reimbursement relevance.
This publication provides a comprehensive overview of 78816, including payer coverage, clinical context, and related policy updates. Readers will gain insight into typical sites of service, such as outpatient hospital settings, and learn about associated modifiers and taxonomies relevant to billing and compliance. The summary also highlights common ICD-10 diagnoses linked to this procedure, such as malignant neoplasms of the lung, breast, prostate, colon, and pancreas. Additionally, comparisons to related CPT codes are included to clarify distinctions in imaging scope and technique.
Healthcare professionals, administrators, and policy analysts will find benchmarks and regulatory updates that inform best practices for coding, billing, and clinical utilization of PET/CT whole body imaging. The article is designed to support informed decision-making and ensure accurate reporting in a rapidly evolving diagnostic landscape.
CPT Code Overview
CPT code 78816 represents a whole body positron emission tomography (PET) scan with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging. This procedure is classified under diagnostic nuclear medicine procedures (PET/CT whole body) and is typically performed in an outpatient hospital setting (POS 22). The combined PET/CT imaging provides comprehensive diagnostic information by integrating metabolic and anatomical data, supporting clinical decision-making in complex cases such as oncology, cardiology, and neurology.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult presenting to an outpatient hospital setting for evaluation of a suspected or known malignancy. The patient may have a diagnosis such as lung cancer, breast cancer, prostate cancer, colon cancer, or pancreatic cancer. The ordering physician requests a whole body positron emission tomography (PET) scan with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization. This imaging procedure assists in initial staging or follow-up assessment of cancer, guiding treatment strategy and monitoring disease progression or response to therapy. The workflow includes patient preparation, radiotracer administration, imaging acquisition, and interpretation by a radiologist or nuclear medicine physician.
Coding Specifications
-
Modifiers:
-
Modifier
PI: Oncologic indications – initial treatment strategy (initial staging). Used when the PET/CT is performed for the first evaluation of a cancer diagnosis. -
Modifier
PS: Oncologic indications – subsequent treatment strategy (follow-up). Used when the PET/CT is performed for monitoring after initial treatment or for ongoing management.
-
-
Provider Taxonomies:
Taxonomy Code Specialty Name 2085R0202XRadiology, Diagnostic Radiology 2085N0700XRadiology, Nuclear Radiology 207U00000XNuclear Medicine Physician
These taxonomies represent providers specializing in diagnostic radiology, nuclear radiology, and nuclear medicine, who are qualified to interpret PET/CT imaging studies.
Related Diagnoses
-
C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung- Relevant for patients undergoing PET/CT for evaluation, staging, or follow-up of lung cancer.
-
C50.919: Malignant neoplasm of unspecified site of unspecified female breast- Used for breast cancer patients requiring whole body PET/CT for staging or monitoring.
-
C61: Malignant neoplasm of prostate- Indicates prostate cancer, where PET/CT may be used to assess metastatic disease or treatment response.
-
C18.9: Malignant neoplasm of colon, unspecified- Applied for colon cancer cases, supporting whole body imaging for staging or surveillance.
-
C25.9: Malignant neoplasm of pancreas, unspecified- Used for pancreatic cancer patients, assisting in comprehensive disease assessment with PET/CT.
Each diagnosis code represents a malignancy commonly evaluated with whole body PET/CT imaging for staging, treatment planning, or follow-up.
Related CPT Codes
-
78815: Positron emission tomography (PET) with concurrently acquired CT for attenuation correction and anatomical localization imaging; limited area (skull base to mid‑thigh)- Used when imaging is limited to a specific region rather than the whole body. May be selected based on clinical indication or payor requirements.
-
78811-78813: PET imaging without concurrent CT (various body regions)- These codes represent PET imaging performed without the CT component. They are alternatives when CT is not required for attenuation correction or anatomical localization.
In clinical workflow, 78816 is used for whole body PET/CT, while 78815 is used for limited area imaging. 78811-78813 are used when only PET imaging is performed, without concurrent CT. Selection depends on clinical need and payor guidelines. These codes are not typically billed together for the same session.